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sitBACKGROUND The randomized EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness
of Left Main Revascularization) trial reported a similar rate of the 3-year composite primary endpoint of death, myocardial
infarction (MI), or stroke in patients with left main coronary artery disease (LMCAD) and site-assessed low or intermediate
SYNTAX scores treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).
Whether these results are consistent in high-risk patients with diabetes, who have fared relatively better with CABG in
most prior trials, is unknown.
OBJECTIVES In this pre-specified subgroup analysis from the EXCEL trial, the authors sought to examine the effect of
diabetes in patients with LMCAD treated with PCI versus CABG.
METHODS Patients (N ¼ 1,905) with LMCAD and site-assessed low or intermediate CAD complexity (SYNTAX
scores #32) were randomized 1:1 to PCI with everolimus-eluting stents versus CABG, stratified by the presence of
diabetes. The primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 years. Outcomes were
examined in patients with (n ¼ 554) and without (n ¼ 1,350) diabetes.
RESULTS The 3-year composite primary endpoint was significantly higher in diabetic compared with nondiabetic
patients (20.0% vs. 12.9%; p < 0.001). The rate of the 3-year primary endpoint was similar after treatment with PCI and
CABG in diabetic patients (20.7% vs. 19.3%, respectively; hazard ratio: 1.03; 95% confidence interval: 0.71 to 1.50;
p ¼ 0.87) and nondiabetic patients (12.9% vs. 12.9%, respectively; hazard ratio: 0.98; 95% confidence interval: 0.73 to
1.32; p ¼ 0.89). All-cause death at 3 years occurred in 13.6% of PCI and 9.0% of CABG patients (p ¼ 0.046), although no
significant interaction was present between diabetes status and treatment for all-cause death (p ¼ 0.22) or other
endpoints, including the 3-year primary endpoint (p ¼ 0.82) or the major secondary endpoints of death, MI, or stroke at
30 days (p ¼ 0.61) or death, MI, stroke, or ischemia-driven revascularization at 3 years (p ¼ 0.65).
CONCLUSIONS In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with everolimus-eluting stents
versus CABG were consistent in diabetic and nondiabetic patients with LMCAD and site-assessed low or intermediate
SYNTAX scores.(Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization [EXCEL]; NCT01205776) (J Am Coll Cardiol 2019;73:1616–28) © 2019 Published by Elsevier on behalf
of the American College of Cardiology Foundation.N 0735-1097/$36.00 https://doi.org/10.1016/j.jacc.2019.01.037
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1617AB BR E V I A T I O N S
AND ACRONYM S
BIMA = bilateral internal
mammary artery
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CI = confidence interval
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
HR = hazard ratio
IDR = ischemia-drivenT he number of people with diabetes mellitusis increasing, having risen from 108 millionin 1980 to 422 million in 2014 (1). Patients
with diabetes are at an increased risk for systemic
atherosclerosis and advanced coronary artery disease
(CAD), and diabetes is a predictor of adverse events
after both coronary artery bypass grafting (CABG)
and percutaneous coronary intervention (PCI) (2,3).
In patients with diabetes and complex anatomic dis-
ease, CABG has been associated with lower mortality
rates compared with PCI (3–5). As a result, CABG has
been recommended as the standard of care for pa-
tients with diabetes and complex CAD including leftSEE PAGE 1629 revascularization
LMCAD = left main coronary
artery disease
MI = myocardial infarction
PCI = percutaneous coronary
intervention
URL = upper reference limitmain coronary artery disease (LMCAD) (6); however,
in a recent pooled analysis of 3 randomized trials
(2 of which were performed more than a decade
ago), patients with diabetes and low or intermediate
anatomic complexity as signified by a SYNTAX score
of #32 had similar 5-year rates after PCI and CABG
of all-cause death, cardiac death, and the composite
of death, myocardial infarction (MI), or stroke (7).
Conversely, patients with high ($33) SYNTAX scores
had significantly higher adverse event rates with PCI
compared with CABG. Since the performance of these
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continued to improve. The extent to which
diabetes thus influences outcomes after
contemporary revascularization strategies in
patients with LMCAD is unknown.
The EXCEL (Evaluation of XIENCE versus
Coronary Artery Bypass Surgery for Effec-
tiveness of Left Main Revascularization) trial
was a large-scale study in which selected
patients with LMCAD were randomized to PCI
with everolimus-eluting stents (EES) versus
CABG (8). Acknowledging the importance of
diabetes, randomization was stratified by the
presence of this variable to ensure a balanced
baseline in the diabetic and nondiabetic
strata. The present report describes the pre-
specified subgroup analysis examining the
impact of diabetes on 30-day and 3-year
outcomes after PCI versus CABG in patients
with LMCAD.METHODS
STUDY DESIGN. The protocol, patient eligibility
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1618in which 1,905 patients with de novo LMCAD and site-
assessed SYNTAX scores #32 in whom equipoise was
present for transcatheter versus surgical revasculari-
zation were randomly (1:1) assigned to undergo PCI
with cobalt–chromium fluoropolymer-based EES
(Abbott Vascular, Santa Clara, California) or CABG.
Patients were assessed for eligibility at each partici-
pating site by a heart team that consisted of (at least)
an interventional cardiologist and a cardiac surgeon
(10). Randomization was stratified according to the
presence of diabetes and site. The trial was approved
by the investigational review board or ethics com-
mittee at each participating center. All patients pro-
vided written informed consent before enrollment.
The trial was funded by Abbott Vascular but led by a
broad academic group with equal representation of
interventional cardiologists and cardiac surgeons
(8,9). The trial is registered at clinicaltrials.gov,
identifier NCT01205776.
ENDPOINTS AND DEFINITIONS. The primary endpoint
was the 3-year rate of all-cause mortality, stroke, or
MI. Major powered secondary outcomes included this
endpoint at 30 days and the composite rate of death,
stroke, MI, or ischemia-driven revascularization (IDR)
at 3 years. Other secondary endpoints included the
components of the primary and secondary endpoints
as well as revascularization, stent thrombosis,
symptomatic graft stenosis or occlusion, and a pre-
specified composite of periprocedural major adverse
events.
The definitions of these outcome measures have
been previously described in detail (8,9). In brief,
stroke was defined as a focal neurological deficit of
central origin lasting >24 h, confirmed by a neurolo-
gist and imaging. Post-procedure MI was defined as
the rise within 72 h after PCI or CABG of creatine
kinase-myocardial band (CK-MB) to >10 the upper
reference limit (URL), or >5 URL plus new patho-
logical Q waves in at least 2 contiguous leads or new
persistent non–rate-related left bundle branch block,
or angiographically documented graft or native cor-
onary artery occlusion or new severe stenosis with
thrombosis and/or diminished epicardial flow, or
imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality. Sponta-
neous MI was defined as the occurrence >72 h after
PCI or CABG of a rise and fall of cardiac biomarkers
(CK-MB or troponin) >1 URL plus electrocardiogram
changes indicative of new ischemia, or development
of pathological Q waves in $2 contiguous electrocar-
diogram leads, or angiographically documented
graft or native coronary artery occlusion or new
severe stenosis with thrombosis and/or diminishedepicardial flow, or imaging evidence of new loss of
viable myocardium or new regional wall motion ab-
normality. Revascularization events were classified
as either ischemia-driven or non–ischemia-driven by
pre-specified criteria (9). An independent clinical
events committee adjudicated all primary and
secondary endpoints with source document
verification.
Patients with diabetes at baseline were categorized
according to treatment as: 1) insulin-treated (with or
without oral hypoglycemic agents); 2) oral hypogly-
cemic agent–treated without insulin; and 3) non-
pharmacological therapy only, including dietary
modification, exercise, and weight reduction. Using
this classification, the following diabetes subgroups
were defined and analyzed in the present study: 1)
insulin-treated patients with or without oral hypo-
glycemic agents; and 2) non–insulin-treated patients
(because only a small number of patients were treated
without medications).
STATISTICAL ANALYSIS. Subgroup analysis accord-
ing to diabetes status with formal interaction testing
was pre-specified in the trial protocol, although no
formal statistical hypothesis was defined a priori. All
analyses were performed with data from the time of
randomization in the intention-to-treat population,
which included all patients according to the group to
which they were randomly assigned, regardless of the
treatment received. Data are summarized using
descriptive statistics, presented as proportions (%,
count/sample size) or mean  SD. Continuous vari-
ables were compared using the Student’s t-test; dif-
ferences in categorical variables were assessed with
the chi-square test or Fisher exact test, as appro-
priate. Event rates were based on Kaplan-Meier esti-
mates in time-to-first-event analyses and were
compared by the log-rank test. Multivariable pre-
dictors of 3-year outcomes were identified using
stepwise selection with a significance level of <0.10
for entry and exit in a logistic regression model. p
Values for interaction were generated by logistic
regression chi-square test. Analyses according to
SYNTAX score tertiles (low 0 to 22, intermediate 23 to
32, high $33) were performed using 3-year Kaplan-
Meier event estimates. All analyses were performed
using SAS software, version 9.4 (SAS Institute, Cary,
North Carolina).
RESULTS
BASELINE AND PROCEDURAL CHARACTERISTICS.
Baseline diabetes status was known in 1,904 of 1,905
randomized patients. Diabetes was present in 554 of








Age, yrs 65.7  9.7 66.5  9.2 0.17
Male 78.0 (10,53/1,350) 74.0 (410/554) 0.06
Body mass index, kg/m2 28.0  4.5 30.4  5.5 <0.001
Hyperlipidemia treated with medication 65.7 (886/1,348) 80.5 (445/553) <0.001
Hypertension treated with medication 68.2 (921/1,350) 87.5 (485/554) <0.001
Current smoker 23.9 (321/1,343) 17.3 (95/548) 0.002
Prior myocardial infarction 17.1 (229/1,339) 18.4 (101/549) 0.50
Congestive heart failure 5.7 (77/1,345) 8.9 (49/553) 0.01
History of carotid artery disease 7.3 (98/1,345) 10.5% (58/551) 0.02
Prior stroke 3.0 (41/1,349) 5.1 (28/554) 0.03
Prior transient ischemic attack 2.8 (38/1,343) 3.5 (19/550) 0.47
Peripheral vascular disease 7.7 (103/1,344) 14.1 (78/552) <0.001
Chronic kidney disease* 14.5 (191/1,320) 21.3 (117/549) <0.001
Anemia† 20.1 (268/1,334) 36.1 (200/554) <0.001
Recent myocardial infarction, within 7 days 15.1 (203/1,345) 14.3 (79/552) 0.66
Unstable angina without recent
myocardial infarction
23.1 (311/1,345) 27.7 (153/552) 0.03
Prior percutaneous coronary intervention 15.3 (206/1,348) 21.7 (120/554) <0.001
Left ventricular ejection fraction, % 57.4  9.1 56.6  9.8 0.19
Society of Thoracic Surgeons score 0.85  0.81 0.96  0.91 0.01
SYNTAX score
Site-assessed 20.5  6.3 20.8  5.9 0.25
0–22 61.8 (833/1,348) 57.1 (316/553) 0.060
23–32 38.2 (515/1,348) 42.9 (237/553) 0.060
$33 0 (0/1,348) 0 (0/553) —
Core laboratory assessed 26.2  9.4 27.3  9.1 0.02
0–22 37.7 (491/1,302) 31.1 (167/537) 0.007
23–32 38.6 (502/1,302) 43.6 (234/537) 0.047
$33 23.7 (309/1,302) 25.3 (136/537) 0.47
Coronary anatomy, core laboratory-assessed
Left main distal bifurcation involvement 56.3 (568/1,009) 62.6 (253/404) 0.03
Number of lesions treated per patient 2.2  0.9 2.3  0.9 0.02
Number of treated non-left main diseased
vessels
1.5  1.0 1.7  1.0 <0.001
0 18.8 (250/1,328) 14.6 (80/549) 0.03
1 32.8 (435/1,328) 27.1 (149/549) 0.02
2 31.3 (416/1,328) 37.2 (204/549) 0.01
3 17.1 (227/1,328) 21.1 (116/549) 0.04
Diffuse disease or small vessels 4.7 (62/1,321) 9.3 (51/549) <0.001
Values are mean  SD or % (n/N). *Estimated glomerular filtration rate <60 ml/min. †Hemoglobin <12 g/dl in
women and <13 g/dl in men.
J A C C V O L . 7 3 , N O . 1 3 , 2 0 1 9 Milojevic et al.
A P R I L 9 , 2 0 1 9 : 1 6 1 6 – 2 8 LMCAD Revascularization With Diabetes
16191,904 patients (29.1%); 147 patients were treated with
insulin, 358 were treated with oral hypoglycemic
agents without insulin, and 49 were treated with
nonpharmacological measures. Patients with diabetes
had a significantly greater number of comorbidities
compared with nondiabetic patients, including hy-
pertension, hyperlipidemia, anemia, renal insuffi-
ciency, peripheral vascular disease, congestive heart
failure, prior stroke, and a higher STS score, although
were less likely to be current smokers (Table 1). By
core laboratory analysis, diabetic patients also had a
higher SYNTAX score, more frequently had diffuse or
small vessel disease, and had a greater number of
treated lesions.
As shown in Table 2, bilateral internal mammary
artery (BIMA) grafting was performed significantly
less frequently in patients with diabetes compared
with patients without diabetes (19.6% vs. 32.4%; p <
0.001). Off-pump CABG technique, total bypass time,
and the number of grafts did not differ between
groups. Mean PCI duration was significantly longer in
diabetic than in nondiabetic patients. There were no
significant differences between the groups in other
PCI procedural aspects. At hospital discharge, no
differences in the administration of antiplatelet
agents, statins, and beta-blockers were found be-
tween diabetic and nondiabetic patients after both
PCI and CABG (Table 2). Medication use during
follow-up is presented in Online Table 1.
THIRTY-DAY OUTCOMES. As shown in Table 3, the
30-day rates of major adverse events were not
significantly different in diabetic compared with
nondiabetic patients; however, in both diabetic and
nondiabetic patients, the 30-day rate of the compos-
ite endpoint of death, stroke, or MI was higher after
CABG than after PCI. The difference in outcome was
driven mainly by higher rates of stroke and MI after
CABG, whereas rates of all-cause death and ischemia-
driven revascularization were similar between CABG
and PCI. Major adverse events were also higher after
CABG than PCI in both diabetic and nondiabetic pa-
tients. Acute renal failure within 30 days occurred
more commonly in patients with diabetes compared
with those without diabetes (2.7% vs. 1.1%; p ¼ 0.01),
and was more frequent after revascularization with
CABG compared with PCI both in patients with (4.1%
vs. 1.4%; p ¼ 0.005) and without (1.9% vs. 0.3%;
p ¼ 0.05) diabetes (pinteraction ¼ 0.44) (Online Table 2).
Among CABG patients, sternal wound dehiscence
occurred in 0.4% versus 1.2% of diabetic and nondi-
abetic patients, respectively (p ¼ 0.26). Furthermore,
sternal dehiscence did not occur more often after the
use of BIMA compared with the single internalmammary artery technique (0% vs. 0.5%; p ¼ 0.68).
There were no significant interactions between dia-
betes status and treatment for any of the 30-day
study endpoints.
3-YEAR OUTCOMES. Clinical outcomes according to
diabetes status and treatment group are shown in
Table 4 and Figure 1. Compared with nondiabetic
patients, diabetic patients had higher 3-year rates of
the composite primary endpoint, including higher
rates of all-cause death, cardiovascular death, MI,
and IDR. The rates of the 3-year composite primary
TABLE 2 Procedural Characteristics and Discharge Medications According to Diabetes Status and Revascularization Assignment














Assigned procedure performed 97.0 (667/688) 95.5 (256/268) 0.28 98.6 (653/662) 98.6 (282/286) 0.96
Time to procedure, days 6.8  15.1 6.5  11.9 0.69 3.4  5.7 3.0  4.1 0.73
Procedure duration, min 241.9  70.9 246.2  69.2 0.37 80.2  41.8 87.7  41.8 0.005
Off-pump CABG 30.1 (201/667) 27.3 (70/256) 0.40 — — —
Bypass time, min 81.6  42.4 87.4  51.0 0.21 — — —
Any internal mammary artery used 99.1 (658/664) 98.0 (250/255) 0.19 — — —
Both internal mammary arteries used 32.4 (215/664) 19.6 (50/255) <0.001 — — —
No. of grafts 2.5  0.8 2.6  0.8 0.50 — — —
No. of stents implanted — — — 2.4  1.5 2.6  1.5 0.08
Total stent length, mm — — — 48.0  35.4 51.7  36.4 0.09
Distal LMCA bifurcation treated — — — 56.7 (366/645) 58.2 (163/280) 0.68
2-stent approach — — — 33.1 (121/366) 39.3 (64/163) 0.17
Crush or mini-crush — — — 10.3 (12/117) 21.9 (14/64) 0.03
FFR used — — — 9.0 (59/653) 8.9 (25/281) 0.95
IVUS used — — — 77.3 (505/653) 77.0 (217/282) 0.90
Duration of hospital stay, days 12.5  9.5 13.2  9.9 0.66 5.4  5.3 5.5  5.1 0.33
Discharge medications
Aspirin 98.9 (651/658) 98.8 (245/248) >0.99 98.9 (641/648) 99.3 (278/280) 0.73
P2Y12 inhibitor 33.7 (223/661) 30.4 (76/250) 0.34 98.3 (639/650) 97.2 (273/281) 0.25
DAPT 33.4 (221/661) 28.8 (72/250) 0.18 97.4 (633/650) 96.1 (270/281) 0.29
Statin 92.6 (612/661) 92.0 (230/250) 0.77 96.0 (624/650) 97.5 (274/281) 0.25
Beta-blocker 92.7 (613/661) 92.0 (230/250) 0.71 83.1 (540/650) 83.6 (235/281) 0.84
ACE inhibitor or ARB 40.7 (269/661) 46.0 (115/250) 0.15 54.8 (154/281) 57.5 (374/650) 0.44
Values are % (n/N) or mean  SD.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blockers; CABG ¼ coronary artery bypass grafting; DAPT ¼ dual antiplatelet therapy; FFR ¼ fractional
flow reserve; IVUS ¼ intravascular ultrasound; LMCA ¼ left main coronary artery; PCI ¼ percutaneous coronary intervention.
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1620endpoint of death, stroke, or MI, or the secondary
composite endpoint of death, stroke, MI, or IDR were
not significantly different between CABG and PCI in
either of the nondiabetic and diabetic cohorts. The 3-
year rate of all-cause death was significantly higher
after PCI compared with CABG in diabetic patients
(13.6% vs. 8.0%; p ¼ 0.046), but not in nondiabetic
patients (5.5% vs. 5.0%; p ¼ 0.71). IDR rates were
lower after CABG compared with PCI in both diabetic
and nondiabetic patients, whereas graft occlusion or
stent thrombosis rates were lower after PCI
compared with CABG. There were no significant in-
teractions between diabetes status and treatment for
any of the 3-year study endpoints, including
mortality.
IMPACT OF INSULIN TREATMENT. Among diabetic
patients, insulin use was associated with greater 3-
year rates of MI and IDR (Online Table 3). The rate
of the 3-year primary composite endpoint of death,
stroke, or MI was similar after PCI and CABG in
both insulin-treated and non–insulin-treated diabetic
patients (Figure 2). There were no significantinteractions between insulin use, revascularization
modality, and 3-year outcomes among diabetic pa-
tients (Online Table 3).
SYNTAX SCORE SUBGROUPS. Analysis according to
site-reported coronary complexity showed a stepwise
increase in 3-year event rates with intermediate
compared with low SYNTAX scores in diabetic pa-
tients, but similar event rates in nondiabetic patients
(Figure 3, Online Table 4). In patients with diabetes
and low SYNTAX scores (0 to 22), no significant 3-year
event rate differences were observed between CABG
and PCI, except for IDR (7.8% vs. 17.0%, respectively;
p ¼ 0.02); however, 3-year mortality was lower after
CABG compared with PCI among the 237 diabetic pa-
tients with intermediate SYNTAX scores (9.6% vs.
19.6%; p ¼ 0.04). However, the interaction between
low versus intermediate site-assessed SYNTAX score
and revascularization modality for 3-year death in
diabetic patients was not significant (p ¼ 0.32).
Among nondiabetic patients, rates of adverse events
were not significantly different after PCI and CABG
irrespective of SYNTAX scores. The results according
TABLE 3 30-Day Clinical Outcomes According to Diabetes Status and Revascularization Assignment



















Death, stroke, or MI 6.0 (80) 7.5 (41) 0.24 7.2 (49) 4.7 (31) 0.06 9.8 (26) 5.3 (15) 0.05 0.61
Death, stroke, MI, or IDR 6.3 (84) 7.6 (42) 0.29 7.8 (53) 4.7 (31) 0.02 10.2 (27) 5.3 (15) 0.03 0.69
Death 0.9 (12) 1.3 (7) 0.46 0.9 (6) 0.9 (6) 0.96 1.5 (4) 1.1 (3) 0.63 0.68
Cardiovascular 0.8 (11) 1.3 (7) 0.36 0.7 (5) 0.9 (6) 0.73 1.5 (4) 1.1 (3) 0.63 0.58
Stroke 0.8 (10) 1.5 (8) 0.15 0.9 (6) 0.6 (4) 0.55 2.3 (6) 0.7 (2) 0.13 0.44
MI 4.9 (66) 5.5 (30) 0.65 6.1 (41) 3.8 (25) 0.06 6.8 (18) 4.2 (12) 0.20 0.98
Periprocedural 4.9 (65) 4.6 (25) 0.77 5.9 (40) 3.8 (25) 0.08 6.1 (16) 3.2 (9) 0.12 0.68
Spontaneous 0.1 (1) 0.9 (5) 0.003 0.1 (1) 0 0.32 0.8 (2) 1.1 (3) 0.72 0.99
All repeat revascularization 1.0 (13) 1.3 (7) 0.56 1.3 (9) 0.6 (4) 0.18 1.5 (4) 1.1 (3) 0.63 0.66
IDR 0.9 (12) 1.3 (7) 0.46 1.3 (9) 0.5 (3) 0.09 1.5 (4) 1.1 (3) 0.63 0.48
PCI 0.5 (7) 1.3 (7) 0.09 0.6 (4) 0.5 (3) 0.74 1.5 (4) 1.1 (3) 0.63 0.92
CABG 0.4 (5) 0 0.15 0.7 (5) 0 0.03 0 0 — >0.99
Graft occlusion or stent thrombosis 0.7 (9) 0.9 (5) 0.59 1.2 (8) 0.2 (1) 0.02 1.1 (3) 0.7 (2) 0.59 0.26
Major adverse events* 15.3 (204) 15.1 (83) 0.92 23.1 (156) 7.3 (48) <0.001 23.5 (62) 7.4 (21) <0.001 0.97
Values are % (n) of Kaplan-Meier time-to-first event estimates. *The composite rate of death, stroke, myocardial infarction, TIMI major or minor bleeding, transfusion $2 U of
blood, major arrhythmia (supraventricular tachycardia requiring cardioversion, ventricular tachycardia or fibrillation requiring treatment, or bradyarrhythmia requiring tem-
porary or permanent pacemaker), ischemia-driven revascularization, any unplanned surgery or therapeutic radiologic procedure, renal failure (serum creatinine increase
by $0.5 mg/dl from baseline or need for dialysis), sternal wound dehiscence, infection requiring antibiotics, or prolonged intubation (>48 h).
IDR ¼ ischemia-driven revascularization; MI ¼ myocardial infarction; other abbreviations as in Table 2.
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1621to core lab adjudication were similar to those from the
site-reported analysis (Online Table 5, Online
Figure 1).
MULTIVARIABLE ANALYSIS. As shown in Online
Tables 6 and 7, diabetes was an independent predic-
tor for the composite endpoint of death, stroke, or MI
after both CABG (hazard ratio [HR]: 1.55; 95% confi-
dence interval [CI]: 1.04 to 2.31; p ¼ 0.03) and PCI
(HR: 1.53; 95% CI: 1.04 to 2.26; p ¼ 0.03). Diabetes wasTABLE 4 3-Year Clinical Outcomes According to Diabetes Status and







Death, stroke, or MI 12.9 (170) 20.0 (109) <0.001 12
Death, stroke, MI, or IDR 18.9 (248) 26.1 (142) <0.001 17
Death 5.3 (69) 10.9 (59) <0.001 5
Cardiovascular 3.1 (41) 6.2 (33) 0.002 3
Stroke 2.3 (30) 3.6 (19) 0.11 2
MI 7.3 (96) 10.5 (56) 0.03 7
Periprocedural 5.0 (67) 4.7 (26) 0.80 6
Spontaneous 2.4 (30) 6.4 (33) <0.001 1
All repeat revascularizations 9.2 (117) 13.1 (68) 0.01 7
IDR 9.0 (115) 12.9 (67) 0.01 7
PCI 7.6 (97) 11.1 (58) 0.01 6
CABG 2.0 (26) 2.2 (11) 0.89 0
Graft occlusion or stent thrombosis 2.6 (34) 4.0 (21) 0.12 4
Values are % (n) of Kaplan-Meier time-to-first event estimates.
Abbreviations as in Tables 2 and 3.also an independent predictor of stroke after CABG
and all-cause death after PCI.
DISCUSSION
The present pre-specified EXCEL substudy examined
the impact of diabetes on clinical outcomes after PCI
with EES versus CABG in patients with LMCAD and
site-assessed low or intermediate SYNTAX scores
(Central Illustration). Compared with nondiabeticRevascularization Assignment














.9 (86) 12.9 (84) 0.89 19.3 (51) 20.7 (58) 0.87 0.82
.5 (116) 20.2 (132) 0.28 22.8 (60) 29.2 (82) 0.17 0.65
.0 (33) 5.5 (36) 0.71 8.0 (21) 13.6 (38) 0.046 0.22
.1 (20) 3.2 (21) 0.85 5.4 (14) 7.0 (19) 0.48 0.68
.3 (15) 2.3 (15) 0.99 5.1 (13) 2.3 (6) 0.08 0.17
.5 (50) 7.1 (46) 0.73 10.8 (28) 10.3 (28) 0.76 0.99
.1 (41) 4.0 (26) 0.09 6.1 (16) 3.5 (10) 0.17 0.81
.6 (10) 3.2 (20) 0.06 5.6 (14) 7.2 (19) 0.50 0.38
.0 (45) 11.3 (72) 0.008 9.1 (23) 16.9 (45) 0.01 0.68
.0 (45) 11.0 (70) 0.01 8.7 (22) 16.9 (45) 0.008 0.51
.1 (39) 9.1 (58) 0.04 8.3 (21) 13.8 (37) 0.058 0.77
.9 (6) 3.1 (20) 0.005 0.4 (1) 3.8 (10) 0.009 0.37
.8 (31) 0.5 (3) <0.001 6.7 (17) 1.5 (4) 0.002 0.32
FIGURE 1 3-Year Outcomes of PCI Versus CABG in Diabetic and Nondiabetic Patients
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Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial infarction (MI); the composite endpoint of all-cause death, stroke, MI, or
ischemia-driven repeat revascularization; all-cause death; and IDR in patients with (A to D) and without (E to H) diabetes. p Values are by log-rank test. CABG ¼ coronary
artery bypass grafting; CI ¼ confidence interval; HR ¼ hazard ratio; IDR ¼ ischemia-driven revascularization; PCI ¼ percutaneous coronary intervention.
Continued on the next page
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1622patients, diabetic patients with LMCAD were at a
nearly 2-fold higher risk for all-cause death, stroke, or
MI at 3 years. There was no significant difference in
the 3-year composite primary endpoint of death,
stroke, or MI or the powered 3-year secondary
endpoint of death, stroke, MI, or IDR after PCI or
CABG either in the diabetic or nondiabetic strata.
Thirty-day adverse events were significantly less af-
ter PCI compared with CABG both in diabetic andnondiabetic patients. Conversely, all-cause mortality
at 3 years was greater after PCI compared with CABG
among diabetic patients with higher site-assessed
SYNTAX scores, although the interaction between
site-assessed SYNTAX score and revascularization
modality for 3-year death in diabetic patients was not
significant. IDR at 3 years was higher with PCI,
whereas graft failure or thrombosis rates were higher
after CABG, both irrespective of diabetic status.
FIGURE 1 Continued
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1623Our findings confirm that diabetes is a critical
determinant of long-term outcomes after myocardial
revascularization (3,4). Currently, no specific recom-
mendation exists concerning the optimal revascular-
ization strategy in diabetic patients with LMCAD (6).
Given the clinical and anatomic complexity that is
frequently present in this high-risk subgroup, the
selection between CABG and PCI in diabetic patients
requires careful consideration. Large-registry data
show a substantial increase in the number of patients
with diabetes and LMCAD undergoing PCI over the
last 20 years, although outcomes data are scarce (11).
Before the present report, comparative effectivenessdata for PCI with drug-eluting stents (DES) versus
CABG in diabetic patients were limited to small sub-
group analyses from clinical trials. In a pooled anal-
ysis of individual patient data from the PRECOMBAT
(Bypass Surgery Versus Angioplasty Using Sirolimus-
Eluting Stent in Patients With Left Main Coronary
Artery Disease) and the SYNTAX (Synergy Between
PCI With TAXUS and Cardiac Surgery) trials, Cav-
alcante et al. (12) found no difference in the occur-
rence of major adverse events between CABG and PCI
with first-generation DES in LMCAD patients with or
without diabetes at 5-year follow-up. The present
results in which second-generation EES and
FIGURE 2 3-Year Outcomes in Patients with Diabetes Stratified by Insulin Treatment
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Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or MI among non–insulin-treated (A) and insulin-treated (B) patients. The p values are by
log-rank test. Abbreviations as in Figure 1.
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1624contemporary CABG techniques were evaluated are
consistent with these findings and indicate that both
revascularization strategies result in comparable
rates of major adverse events at 3 years.
Although PCI resulted in substantially fewer ma-
jor adverse events at 30 days in both diabetic and
nondiabetic patients, an important consideration
affecting the selection of revascularization proced-
ure is long-term survival. In this regard, a large
propensity-matched analysis of 4,048 patient-pairs
from the New York State outcomes registries sug-
gested that the apparent survival benefit of CABG
over PCI in diabetic patients in the FREEDOM
(Comparison of Two Treatments for Multivessel
Coronary Artery Disease in Individuals With Dia-
betes) and SYNTAX trials (3,4) might be lost when
PCI was performed with EES (13); however, registries
are particularly sensitive to the occurrence of se-
lection bias, and these results must be interpreted
with caution (14). Among the 554 diabetic patients
randomized in the EXCEL trial, a significant differ-
ence in mortality between CABG and PCI was
observed in those with higher SYNTAX scores;
however, the EXCEL trial was not powered for
mortality in the entire population, let alone the
diabetic subgroup, and no interaction was noted
between diabetic status, revascularization, and3-year mortality. In a recently published pooled
analysis of individual randomized patient data (15)
from the SYNTAX, PRECOMBAT, EXCEL, and NO-
BLE (PCI vs. CABG in the Treatment of Unprotected
Left Main Stenosis) trials (8,16–18), there was no
significant difference in 5-year mortality after
treatment of 4,478 patients with LMCAD with PCI
versus CABG (10.7% vs. 10.5%; HR: 1.07; 95% CI:
0.87 to 1.33; p ¼ 0.52), either in patients with
(n ¼ 1,120; HR: 1.34; 95% CI: 0.93 to 1.31) or without
(n ¼ 3,358; HR: 0.94; 95% CI: 0.72 to 1.23) diabetes.
In this analysis, CABG did, however, result in su-
perior survival to PCI in diabetic patients with
multivessel disease (but without LMCA involve-
ment), again suggesting that in general patients with
diabetes and complex CAD may preferentially
benefit by CABG.
Finally, despite the fact that evidence supports the
recommendation of increasing use of BIMA grafts
during CABG in diabetic patients who are at low risk
of deep sternal wound infection (6,19,20), rates of
BIMA usage are still relatively low (only 19.6% of
diabetic patients in the present trial). No significant
differences in sternal wound dehiscence were
observed in diabetic patients treated with a single
internal mammary artery versus BIMA in the EXCEL
trial. It is also noteworthy that adherence rates to
FIGURE 3 3-Year Outcomes for Diabetic and Nondiabetic Patients According to Anatomic Lesion Complexity as Measured by the
Site-Assessed SYNTAX Score
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Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or MI; the composite endpoint of all-cause death, stroke, MI, or
ischemia-driven repeat revascularization (IDR); all-cause death; and IDR in diabetic patients (A to D) and nondiabetic patients (E to H).
Treatment by SYNTAX score interactions in the diabetic and the nondiabetic groups: The composite endpoint of all-cause death, stroke, or MI
(pint ¼ 0.81 and pint ¼ 0.98); the composite endpoint of all-cause death, stroke, MI, or IDR (pint ¼ 0.87 and pint ¼ 0.31); all-cause death
(pint ¼ 0.32 and pint ¼ 0.40); and IDR (pint ¼ 0.63 and pint ¼ 0.10). p Values are by log-rank test. Rates are separated according to the site-
reported SYNTAX score values, indicating low (0 to 22) and intermediate (23 to 32) anatomic lesion complexity. SYNTAX ¼ Synergy Between
PCI With TAXUS and Cardiac Surgery; other abbreviations as in Figure 1.
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CENTRAL ILLUSTRATION Impact of Diabetes Mellitus on 3-Year Outcomes After Left Main
Revascularization
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Diabetes Versus Non-DiabetesA
PCI Versus CABGB
Milojevic, M. et al. J Am Coll Cardiol. 2019;73(13):1616–28.
The incidence rates of the primary composite endpoint of death, stroke, or MI among diabetic and non-diabetic patients (A) and according to
the type of revascularization procedure (B) are shown. Over the 3-year follow-up period, PCI with EES compared with CABG was associated
with similar risk of the primary composite endpoint among both diabetic and nondiabetic patients. CABG ¼ coronary artery bypass grafting;
CI ¼ confidence interval; DM ¼ diabetes mellitus; EES ¼ everolimus-eluting stents; HR ¼ hazard ratio; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Patients with diabetes mellitus and LMCAD undergoing
myocardial revascularization are at higher risk of mortality and
major adverse events than those without diabetes. In a
randomized trial, there was no difference in the 3-year composite
endpoint of all-cause death, stroke, or myocardial infarction
between PCI and CABG, irrespective of baseline diabetes status.
TRANSLATIONAL OUTLOOK: Although CABG remains the
standard of care for diabetic patients with complex CAD, further
studies are needed to ascertain the characteristics of patients
with diabetes who can be appropriately managed by
percutaneous intervention.
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1627guideline-directed medication therapy after CABG
have reached 90% in the EXCEL trial (21) but remain
lower than after PCI. Of note, approximately one-
third of CABG patients were discharged on dual an-
tiplatelet therapy, which, although less than after
PCI, represents a higher percentage than in some
other studies. This may reflect appropriate use after
CABG in patients presenting with acute coronary
syndromes, as well as the potential for dual anti-
platelet therapy to enhance graft patency (22), the
topic of several ongoing randomized controlled trials
(Ticagrelor Antiplatelet Therapy to Reduce Graft
Events and Thrombosis [TARGET], NCT02053909;
Effect of Ticagrelor on Saphenous Vein Graft Patency
in Patients Undergoing Coronary Artery Bypass
Grafting Surgery [POPular CABG], NCT02352402;
Study Comparing Ticagrelor With Aspirin for Pre-
vention of Vascular Events in Patients Undergoing
CABG [TiCAB], NCT01755520). Optimizing guideline-
directed medication therapy after both CABG and
PCI is essential for patients to derive the most bene-
fits from revascularization.
STUDY LIMITATIONS. Although randomization was
stratified by diabetes status, and the diabetes sub-
group analysis was pre-specified in the EXCEL trial
design, the present study was not powered to detect
a difference in the primary endpoint of death, stroke,
or MI between PCI and CABG in the diabetic cohort,
and secondary outcome measures were not adjusted
for multiple comparisons. Hence, the results of the
present study should be interpreted as hypothesis-
generating only, and further investigation in dedi-
cated trials of diabetic patients are warranted (23,24).
In addition, the EXCEL trial enrolled patients with
LMCAD and site-assessed low or intermediate SYN-
TAX scores who were eligible to undergo both PCI
and CABG. Therefore, these findings cannot be
extrapolated either to patients with unacceptable
high surgical risk or patients with coronary anatomy
unsuitable for PCI. A major focus of diabetes man-
agement is optimal glycemic control. Recently, the
use of gliflozins has been shown to reduce the risk of
major cardiovascular events in patients with type 2
diabetes (25). Unfortunately, the use of specific oral
hypoglycemic agents and data on long-term glycemiccontrol were not collected in the present study.
Finally, follow-up in the EXCEL trial is complete only
through 3 years; longer-term surveillance is neces-
sary to examine whether additional differences
emerge over time.
CONCLUSIONS
In the large-scale EXCEL trial, among both diabetic
and nondiabetic patients with LMCAD and site-
assessed low-to-intermediate (#32) SYNTAX scores,
PCI using EES and CABG resulted in similar rates of
the primary composite endpoint of death, stroke, or
MI at 3-year follow-up, although fewer adverse
events at 30 days occurred after PCI. For diabetic
patients with LMCAD and relatively noncomplex
coronary anatomy, PCI may be a reasonable approach,
whereas CABG should be considered for diabetic pa-
tients with more complex CAD.
ADDRESS FOR CORRESPONDENCE: Prof. Arie Pieter
Kappetein, Department of Cardio-Thoracic Surgery,
Erasmus University Medical Center, P.O. Box 2040,
3000 CA Rotterdam, the Netherlands. E-mail: a.
kappetein@erasmusmc.nl. Twitter: @kandzari,
@Drroxmehran, @philgenereux, @AKappetein,
@DrChuckSimonton, @GreggWStone.RE F E RENCE S1. Roglic G. WHO global report on diabetes:
a summary. Int J Noncommun Dis 2016;1:3–8.
2. Kappetein AP, Head SJ. CABG or
PCI for revascularisation in patients with dia-
betes? Lancet Diabetes Endocrinol 2013;1:
266–8.3. Kappetein AP, Head SJ, Morice MC, et al.
Treatment of complex coronary artery disease in
patients with diabetes: 5-year results comparing
outcomes of bypass surgery and percutaneous
coronary intervention in the SYNTAX trial. Eur J
Cardiothorac Surg 2013;43:1006–13.4. Farkouh ME, Domanski M, Sleeper LA, et al.
Strategies for multivessel revascularization in pa-
tients with diabetes. N Engl J Med 2012;367:
2375–84.
5. Verma S, Farkouh ME, Yanagawa B, et al.
Comparison of coronary artery bypass surgery and
Milojevic et al. J A C C V O L . 7 3 , N O . 1 3 , 2 0 1 9
LMCAD Revascularization With Diabetes A P R I L 9 , 2 0 1 9 : 1 6 1 6 – 2 8
1628percutaneous coronary intervention in patients
with diabetes: a meta-analysis of randomised
controlled trials. Lancet Diabetes Endocrinol 2013;
1:317–28.
6. Sousa-Uva M, Neumann F-J, Ahlsson A, et al.
2018 ESC/EACTS guidelines on myocardial
revascularization: the Task Force on Myocardial
Revascularization of the European Society of
Cardiology (ESC) and the European Association
for Cardio-Thoracic Surgery (EACTS). Eur J Car-
diothorac Surg 2019;55:4–90.
7. Cavalcante R, Sotomi Y, Mancone M, et al.
Impact of the SYNTAX scores I and II in patients
with diabetes and multivessel coronary disease: a
pooled analysis of patient level data from the
SYNTAX, PRECOMBAT, and BEST trials. Eur Heart J
2017;38:1969–77.
8. Stone GW, Sabik JF, Serruys PW, et al. Ever-
olimus-eluting stents or bypass surgery for left
main coronary artery disease. N Engl J Med 2016;
375:2223–35.
9. Kappetein AP, Serruys PW, Sabik JF, et al.
Design and rationale for a randomised comparison
of everolimus-eluting stents and coronary artery
bypass graft surgery in selected patients with left
main coronary artery disease: the EXCEL trial.
EuroIntervention 2016;12:861–72.
10. Head SJ, Kaul S, Mack MJ, et al. The rationale
for heart team decision-making for patients with
stable, complex coronary artery disease. Eur Heart
J 2013;34:2510–8.
11. Lee PH, Ahn JM, Chang M, et al. Left main
coronary artery disease: secular trends in patient
characteristics, treatments, and outcomes. J Am
Coll Cardiol 2016;68:1233–46.
12. Cavalcante R, Sotomi Y, Lee CW, et al. Out-
comes after percutaneous coronary intervention or
bypass surgery in patients with unprotected leftmain disease. J Am Coll Cardiol 2016;68:
999–1009.
13. Bangalore S, Guo Y, Samadashvili Z, Blecker S,
Xu J, Hannan EL. Everolimus eluting stents versus
coronary artery bypass graft surgery for patients
with diabetes mellitus and multivessel disease.
Circ Cardiovasc Interv 2015;8:e002626.
14. Ferreira-Gonzalez I, Marsal JR, Mitjavila F,
et al. Patient registries of acute coronary syn-
drome: assessing or biasing the clinical real world
data? Circ Cardiovasc Qual Outcomes 2009;2:
540–7.
15. Head SJ, Milojevic M, Daemen J, et al. Mor-
tality after coronary artery bypass grafting versus
percutaneous coronary intervention with stenting
for coronary artery disease: a pooled analysis of
individual patient data. Lancet 2018;391:939–48.
16. Mohr FW, Morice MC, Kappetein AP, et al.
Coronary artery bypass graft surgery versus
percutaneous coronary intervention in patients
with three-vessel disease and left main coronary
disease: 5-year follow-up of the randomised,
clinical SYNTAX trial. Lancet 2013;381:629–38.
17. Ahn JM, Roh JH, Kim YH, et al. Randomized
trial of stents versus bypass surgery for left main
coronary artery disease: 5-year outcomes of the
PRECOMBAT study. J Am Coll Cardiol 2015;65:
2198–206.
18. Makikallio T, Holm NR, Lindsay M, et al.
Percutaneous coronary angioplasty versus coro-
nary artery bypass grafting in treatment of un-
protected left main stenosis (NOBLE): a
prospective, randomised, open-label, non-inferi-
ority trial. Lancet 2016;388:2743–52.
19. Aldea GS, Bakaeen FG, Pal J, et al. The Society
of Thoracic Surgeons clinical practice guidelines on
arterial conduits for coronary artery bypass
grafting. Ann Thorac Surg 2016;101:801–9.20. Raza S, Sabik JF 3rd, Masabni K, Ainkaran P,
Lytle BW, Blackstone EH. Surgical revasculariza-
tion techniques that minimize surgical risk and
maximize late survival after coronary artery
bypass grafting in patients with diabetes mellitus.
J Thorac Cardiovasc Surg 2014;148:1257–64; dis-
cussion 64–6.
21. Pinho-Gomes AC, Azevedo L, Ahn JM, et al.
Compliance with guideline-directed medical ther-
apy in contemporary coronary revascularization
trials. J Am Coll Cardiol 2018;71:591–602.
22. Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor
plus aspirin, ticagrelor alone, or aspirin alone on
saphenous vein graft patency 1 year after coronary
artery bypass grafting: a randomized clinical trial.
JAMA 2018;319:1677–86.
23. Head SJ, Kaul S, Tijssen JG, Serruys PW,
Kappetein AP. Subgroup analyses in trial reports
comparing percutaneous coronary intervention
with coronary artery bypass surgery. JAMA 2013;
310:2097–8.
24. Althouse AD. Adjust for multiple comparisons?
It’s not that simple. Ann Thorac Surg 2016;101:
1644–5.
25. Neal B, Perkovic V, Mahaffey KW, et al. Can-
agliflozin and cardiovascular and renal events in
type 2 diabetes. N Engl J Med 2017;377:644–57.KEY WORDS coronary artery bypass
grafting, diabetes, left main disease,
percutaneous coronary intervention, SYNTAX
scoreAPPENDIX For supplemental tables and a
figure, please see the online version of this
paper.
